文献速递临床试验与 GCP基础与转化研究

流感血凝素茎部纳米颗粒疫苗在健康成人中诱导1组交叉中和抗体

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
PubMed 文献 · Sci Transl Med · 2023-04-19

这项首次人体、剂量递增、开放标签1期临床试验(NCT03814720)测试了基于A/New Caledonia/20/1999 H1血凝素茎部的铁蛋白纳米颗粒疫苗H1ssF。52名18至70岁健康成人入组,接受20 μg H1ssF一次(n=5)或60 μg H1ssF两次(n=47),初免-加强间隔16周。H1ssF安全且耐受良好,诱导了针对1组流感病毒保守HA茎部的交叉反应性中和抗体,且应答持久,接种后1年以上仍可观察到中和抗体。

要点

  • H1ssF在健康成人中安全且耐受良好,最常见为注射部位疼痛或压痛(n=10,19%)、头痛(n=10,19%)和不适(n=6,12%)。
  • H1ssF诱导了针对1组流感病毒保守HA茎部的交叉反应性中和抗体。
  • 中和抗体应答持久,接种后1年以上仍可观察到。

核心结论

  • H1ssF安全且耐受良好,诱导了针对1组流感病毒保守HA茎部的交叉反应性中和抗体,且应答持久,接种后1年以上仍可观察到中和抗体。
  • 结果支持该平台作为通用流感疫苗开发向前迈出的一步。

研究设计与样本

  • 首次人体、剂量递增、开放标签1期临床试验(NCT03814720)。
  • 52名18至70岁健康成人入组,接受20 μg H1ssF一次(n=5)或60 μg H1ssF两次(n=47),初免-加强间隔16周。
  • 60 μg剂量组中35名(74%)参与者接受了加强接种,11名(23%)因COVID-19大流行早期的公共卫生限制而错过加强接种。
  • 主要目标为评估H1ssF的安全性和耐受性,次要目标为评估接种后的抗体应答。

主要发现

  • H1ssF安全且耐受良好,仅有轻度征集性局部和全身反应原性。
  • 最常见症状包括注射部位疼痛或压痛(n=10,19%)、头痛(n=10,19%)和不适(n=6,12%)。
  • H1ssF诱导了针对1组流感病毒保守HA茎部的交叉反应性中和抗体,尽管既往存在H1亚型头部特异性免疫。
  • 中和抗体应答持久,接种后1年以上仍可观察到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 60 μg剂量组中11名(23%)参与者因COVID-19大流行早期的公共卫生限制而错过加强接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza vaccines could be improved by platforms inducing cross-reactive immunity. Immunodominance of the influenza hemagglutinin (HA) head in currently licensed vaccines impedes induction of cross-reactive neutralizing stem-directed antibodies. A vaccine without the variable HA head domain has the potential to focus the immune response on the conserved HA stem. This first-in-human dose-escalation open-label phase 1 clinical trial (NCT03814720) tested an HA stabilized stem ferritin nanoparticle vaccine (H1ssF) based on the H1 HA stem of A/New Caledonia/20/1999. Fifty-two healthy adults aged 18 to 70 years old enrolled to receive either 20 μg of H1ssF once (n = 5) or 60 μg of H1ssF twice (n = 47) with a prime-boost interval of 16 weeks. Thirty-five (74%) 60-μg dose participants received the boost, whereas 11 (23%) boost vaccinations were missed because of public health restrictions in the early stages of the COVID-19 pandemic. The primary objective of this trial was to evaluate the safety and tolerability of H1ssF, and the secondary objective was to evaluate antibody responses after vaccination. H1ssF was safe and well tolerated, with mild solicited local and systemic reactogenicity. The most common symptoms included pain or tenderness at the injection site (n = 10, 19%), headache (n = 10, 19%), and malaise (n = 6, 12%). We found that H1ssF elicited cross-reactive neutralizing antibodies against the conserved HA stem of group 1 influenza viruses, despite previous H1 subtype head-specific immunity. These responses were durable, with neutralizing antibodies observed more than 1 year after vaccination. Our results support this platform as a step forward in the development of a universal influenza vaccine.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Widge AT, Hofstetter AR, Houser KV, et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci Transl Med. 2023. PMID: 37075129. doi:10.1126/scitranslmed.ade4790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。